BACKGROUND: Next-generation sequencing of cell-free DNA (cfDNA) has been shown to be a useful noninvasive test for detecting mutations in solid tumors. METHODS: Targeted gene sequencing was performed with a panel of 263 cancer-related genes for cfDNA and genomic DNA of peripheral blood mononuclear cells (PBMCs) obtained from presurgical specimens of 6 lung cancer patients, and mutation calls in these samples were compared with those of primary tumors and corresponding patient-derived xenografts (PDXs). RESULTS: Approximately 67% of the mutations detected in the tumor samples (primary tumors and/or PDXs) were also detected in genomic DNA from PBMCs as background mutations. These background mutations consisted of germline polymorphisms and a group of mutations with low allele frequencies, mostly <10%. These variants with a low allele frequency were repeatedly detected in all types of samples from the same patients and at similarly low allele frequency levels in PBMCs from different patients; this indicated that their detection might be derived from common causes, such as homologous sequences in the human genome. Allele frequencies of mutations detected in both primary tumors and cfDNA showed 2 patterns: 1) low allele frequencies (approximately 1%-10%) in cfDNA but high allele frequencies (usually >10% or >3-fold increase) in primary tumors and further enrichment in PDXs and 2) similar allele frequencies across samples. CONCLUSIONS: Because only a small fraction of total cfDNA might be derived from tumor cells, only mutations with the first allele frequency pattern may be regarded as tumor-specific mutations in cfDNA. Effective filtering of background mutations will be required to improve the accuracy of mutation calls in cfDNA.
INTRODUCTION
Emerging evidence has shown that droplet digital polymerase chain reaction and next-generation sequencing of cell-free DNA (cfDNA) can be used to detect tumor-specific alterations, such as mutations, translocations, aberrant methylations, and copy number alterations. [1] [2] [3] Fragments of cfDNA are released from dead cells and are present at low concentrations in body fluids, including plasma, serum, cerebrospinal fluid, and urine. 4, 5 Circulating cfDNA is detectable in the plasma and serum of healthy individuals, but its levels increase after acute physical exercise, 6 during pregnancy, 7, 8 and under pathologic conditions associated with increased cell death, such as inflammation, 9 myocardial infarction, 10, 11 burns, 12 and transplantation rejection. 13, 14 Circulating cfDNA levels are also drastically increased in patients with various cancers. [15] [16] [17] Plasma cfDNA isolated from healthy individuals or patients with benign diseases has been shown to consist of small fragments corresponding to multiplied amounts (1-53) of nucleosomal DNA (approximately 150-200 base pairs), 18, 19 and this suggests that most circulating cfDNA is derived from apoptotic cells. An increase in the number of nonapoptotic DNA fragments (both larger and smaller than apoptotic DNA fragments) in plasma cfDNA was often detected in samples obtained from cancer patients, 19, 20 and this indicated that cfDNA in these patients may have been derived from not only apoptosis but also necrosis, or mitotic catastrophe. Thus, the testing of circulating cfDNA is potentially a unique noninvasive diagnostic approach to the early detection of cancer and identification of actionable genomic alterations to guide precision medicine. The relatively short (approximately 16-minute) half-life of circulating cfDNA 21 allows longitudinal samples to be used to monitor treatment responses, disease recurrence, and the emergence of treatment-resistant mutations. 22 In addition, blood flows through both primary and metastatic tumors; therefore, the genomic profile of cfDNA is thought to be a representative readout of collective genomic alterations in all tumors in a patient, including primary and metastatic tumor nodules. This avoids the potential problems of conventional biopsy that result from the observed spatial heterogeneity in a variety of cancers. However, the accuracy of using cfDNA to screen for genomic mutations associated with cancer has not yet been fully examined.
We recently described the molecular characteristics of 23 patient-derived xenografts (PDXs) established from surgical lung tumor samples via exome sequencing with a platform consisting of 202 cancer-related genes (the T200 platform), which was developed at the Institute for Personalized Cancer Therapy Genomic Laboratory at The University of Texas MD Anderson Cancer Center. 23, 24 Our results demonstrated that 93% of the mutations detected in primary tumors were also detected in PDXs, and this indicated that PDXs could recapitulate the mutations in primary tumors. 24 In the current study, to determine whether the mutations detected in both primary tumors and PDXs could also be detected in plasma samples, we performed targeted gene sequencing of DNA samples isolated from plasma and peripheral blood mononuclear cells (PBMCs) obtained from 6 lung cancer patients whose plasma and PBMC samples were collected before surgery. Exome sequencing of cfDNA and DNA from PBMCs was then performed on the upgraded T200.1 platform, which covers 263 cancer-associated genes, including 142 genes on the original T200 platform.
By comparing the mutation profiles in 4 types of samples (primary tumors, PDXs, PBMCs, and cfDNA) obtained from the same patients for the 142 overlapping genes in the 2 data sets, we found that tumor-specific mutations had low allele frequencies in cfDNA but much higher allele frequencies in primary tumors and/or PDXs. However, a number of variants with low allele frequencies were detected across all types of samples, including genomic DNA from PBMCs, and this limits the interpretation of mutations detected in cfDNA only. Our results indicate that 2 procedures are needed to improve the accuracy of mutation calls in cfDNA: 1) the effective filtering of background mutations with PBMCs as a control and 2) the removal of false-positives possibly derived from repetitive sequences.
MATERIALS AND METHODS

Patient Plasma and White Blood Samples
Presurgical blood samples (approximately 5 mL) were collected in sterile tubes coated with ethylenediaminetetraacetic acid (EDTA) as an anticoagulant immediately before surgery for lung cancer resections under approved research protocols with informed consent from the patients. The study was approved by the institutional review board at MD Anderson. The blood samples were processed for the isolation of plasma and white blood cells within the first 8 hours after sample collection. Briefly, blood samples were centrifuged at 2500 rpm for 10 minutes at room temperature to separate plasma from blood cells. Red blood cells were then lysed with 4 volumes (approximately 10 mL) of sterile red blood cell lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM Na 2 ÁEDTA at pH 7.4) to obtain white blood cells. Both white blood cells and plasma samples were cryopreserved at -808C until they were used for DNA isolation.
Preparation of DNA Samples
White blood cells suspended in 75 mM NaCl and 25 mM ETDA were digested with proteinase K (50 lg/mL) in the presence of 0.5% sodium dodecyl sulfate for 3 hours at 558C. The samples were then extracted with phenol, chloroform, and isoamyl alcohol (25:24:1) and precipitated with 2-propanol. The DNA pellet was dissolved in 10 mM Tris-Cl and 1 mM EDTA buffer (pH 8.0). The DNA in the plasma sample was isolated from 1 to 2 mL of plasma per sample via proteinase digestion, phenol-chloroformisoamyl alcohol extraction, and 2-propanol precipitation. Glycogen (final concentration, 20 lg/mL) was added to the solution for the precipitation of cfDNA by 2-propanol. DNA concentrations were determined with the Quant-iT PicoGreen double-stranded DNA assay kit (Thermo Fisher) according to the manufacturer's instructions.
Targeted Gene Sequencing for 263 Cancer-Related Genes and Data Analysis
Targeted gene sequencing for exonic regions of 263 genes was performed at the Institute for Personalized Cancer Therapy Genomic Laboratory at MD Anderson. The
Original Article preparation of DNA libraries, the capture of target sequences, and the next-generation sequencing of captured libraries were performed as described previously, 23, 24 except that the sequencing platform was upgraded to version T200.1, which consists of 263 genes (Supporting Table 1 [see online supporting information]), 142 of which were on the original T200 platform. For most samples, 100 to 200 ng of DNA was used for library generation; however, 1 sample had only 8.1 ng used for library generation. The data analysis was performed as previously described. 24 
Statistical Analysis
We determined agreement on mutations among samples by querying genomic loci, gene names, and nucleotide changes at the same codes in different types of samples. Descriptive statistics were determined for the distributions of allele frequencies in each sample, and multiple regression analysis was used to determine the allele frequencies of the same mutations in different samples with the SPSS v22 package. P < .05 was considered statistically significant in the regression analyses.
RESULTS
Mutations Detected in Different Types of Samples
We previously determined gene mutations in PDXs and their primary tumors via targeted gene sequencing in 202 cancer-related genes and found that 93% of the mutations detected in primary tumors were also detected in their corresponding PDXs. 24 To determine whether these mutations could also be detected in cfDNA, we isolated genomic DNA from white blood cells and cfDNA from plasma from 6 patients whose presurgical blood samples were available for analysis. The clinical information for these 6 patients is summarized in Table 1 . The tumor volume varied from 5.6 to 252 cm 3 . Plasma cfDNA was isolated from 1 to 2 mL of frozen plasma. The final yield of cfDNA was greater than 150 ng for 5 samples and was 8.1 ng for 1 sample. Nevertheless, enough DNA was generated for all samples by 6 cycles of polymerase chain reaction during library preparation for target sequencing. Therefore, all samples were processed for the analysis of targeted gene sequencing.
When the PBMC and cfDNA samples were ready for analysis, the sequencing platform at our institutional Sequencing and Microarray Core Facility was upgraded to version T200.1, which consists of 263 genes, 142 of which were on the original T200 platform that was used for the analysis of PDXs and their primary tumors in our previous study (Supporting Table 1 [see online supporting information]). The average coverage for each data point was 899 reads in the sequencing analysis performed on the T200 platform with PDX and primary lung tumor samples, whereas the average coverage on the T200.1 platform with PBMC and cfDNA samples was 682 reads. We compared the mutations in the common 142 genes that were analyzed on both the T200 platform (for PDX and primary tumor samples) and the T200.1 platform (for PBMC and cfDNA samples). Because only a small fraction of total cfDNA might be derived from tumor cells, we used a 1% allele frequency as a cutoff for all sample types. Table 2 lists the number of mutations detected in each sample by type.
Approximately 120 to 150 mutation calls were detected in all sample types including PBMCs, cfDNA, primary tumors, and PDXs, and a variable number of mutations (range: 6-95) were detected among PBMCs, cfDNA, primary tumors, and PDXs. The percentage of mutations detected in both primary tumors/PDXs and PBMCs, including those detected in all sample types, ranged from 49% to 86% with an average of 67%. This result suggested that a substantial number of mutations may be detectable in genomic DNA isolated from patients' PBMCs.
Mutations Detected in PBMCs
We determined the distribution of mutations detected in PBMCs on the basis of allele frequencies, and we found that the number of mutations detected in all types of samples (PBMCs, cfDNA, primary tumors, and PDXs) usually peaked around allele frequencies of 95% to 100%, 40% to 60%, and <10% (Fig. 1) . The mutation calls with allele frequencies of 95% to 100% and 40% to 60% were likely the single-nucleotide polymorphisms present in germline DNA as homozygotes and heterozygotes. However, numerous mutations were detected at low allele frequencies (most of them at <10%) in PBMCs, which are regarded as germline DNA. The nature of the mutations with low allele frequencies detected in PBMCs is not clear. Because these mutations were detected in different types of samples, it is likely that they are derived from a common cause, such as repetitive or homologous sequences in the genome. We next compared allele frequencies of mutations detected in PBMCs with those of mutations detected in other types of samples from the same patient. The allele frequencies of mutations detected in both PBMCs and cfDNA from the same patients were almost identical (R 5 0.998; P 5 .000; Fig. 2 ). The allele frequencies of mutations detected in both PBMCs and primary tumors/PDXs were almost identical (R 5 0.968-0.979; P 5 .000) for most mutations detected in these types of samples. However, for some mutations whose allele frequencies were approximately 50% in PBMCs, the allele frequencies were substantially different in the primary tumors/PDXs, and this suggests that some loss of heterogeneity might have occurred in these alleles. To determine whether tumor-specific mutations could be detected in cfDNA, we analyzed mutations present in both the cfDNA and the primary tumor or PDX but not in the PBMCs. The patients had 4 to 45 mutations detected in these types of samples (Fig. 3) . With a few exceptions, most of these mutations had allele frequencies < 10% in the cfDNA, and most of the allele frequencies were within 5% in the cfDNA. As shown in Figure 4 , 27 of 45 mutations detected in the primary tumor and cfDNA in 1 of the patients had a >10% allele frequency in the primary tumor or at least a 3-fold increase in the allele frequency in the primary tumor versus the cfDNA. All 27 of these mutations were detected in PDXs, which showed increased allele frequencies in comparison with the primary tumor. For the remaining 18 mutations, 15 had allele frequencies in the primary tumor or PDX similar to those observed in the cfDNA; all were <10%. This pattern was similar to that of mutations that were detected in all samples with low allele frequencies. The remaining 3 are likely homozygote/heterozygote polymorphisms that were missed in PBMCs. Together, these 18 mutations are likely not tumor-specific mutations, but their detection was missed in PBMCs. If enrichment of allele frequencies in the primary tumor and PDX were used as a criterion for tumorspecific mutations detected in cfDNA, only 2 additional mutations (1 each for patient TC137 and patient TC145) could be considered tumor-specific. The others were either noise (mostly with allele frequencies < 10%) or germline polymorphisms (allele frequencies > 40%; see Fig. 3 ) that were missed in the PBMCs. Similarly, 55 of the 331 mutations listed as appearing in the primary tumor only in Table 2 may qualify as tumor-specific mutations because the remaining mutations had allele frequencies < 10% and were either not detected or enriched in PDXs (data not shown).
Because the coverage depth for samples analyzed on the T200.1 platform was lower than that for those analyzed on the T200 platform and because the tumorspecific mutations detected in the cfDNA might have allele frequencies lower than 1%, we further checked variants in cfDNA with allele frequencies < 1% for tumorspecific mutations. Another 26 mutations were identified in 6 cfDNA samples that were also detected in their tumors/PDXs; the number ranged from 1 to 10 per sample. Among them, 2 had dramatic enrichment in allele frequencies in primary tumors/PDXs, whereas the remaining 24 mutations had similarly low allele frequencies in primary tumors/PDXs (data not shown).
Recurrence of Mutations With Low Allele Frequencies in PBMCs
The fact that some mutations had similarly low allele frequencies in different types of samples, including PBMCs, from the same patient (Fig. 2) suggested that these mutations might be derived from common sources and not as a result of a random event such as an error introduced during polymerase chain reaction for library preparation. One possible explanation could be the homologous sequences of the testing exome in the genome. In this case, we might expect to detect the same mutations with low allele frequencies in PBMCs from different patients. Therefore, we analyzed whether the mutations with allele frequencies of 1% to 15% were detected recurrently in PBMCs from the 6 lung cancer patients. We found that 89 of 126 such mutations (approximately 71%) were detected in 2 or more PBMC samples (Fig. 5) . This result supports the interpretation that most of the mutations with low allele frequencies detected in PBMCs might be derived from some common source during the assay, such as homologous sequences in the human genome.
DISCUSSION
We compared mutations via the targeted gene sequencing of 142 cancer-related genes in 4 types of samples from lung cancer patients: cfDNA, PBMCs, primary tumors, and PDXs. Our results showed that tumor-specific mutations could be detected in some cfDNA samples, even though the assays were performed at different times and with different assay platforms. The allele frequencies of the tumor-specific mutations in cfDNA ranged from 1% to 10%. Nevertheless, a large number of background mutations with allele frequencies < 15% were detected in all 4 types of samples from the same patients, with similar allele frequencies among these samples. Because tumorspecific mutations detected in cfDNA have similarly low allele frequencies, it is challenging to distinguish mutations from background noise if cfDNA is analyzed alone. Our results indicate that the simultaneous analysis of cfDNA and PBMCs is necessary to filter out background mutations if the primary tumor sample is not available.
A recent report showed that variations in sample preparations, sequencing methods, and data analysis pipelines in next-generation sequencing used by different research teams or investigators often lead to significant variation in the accuracy of mutation calls. 25 For example, The Cancer Genome Atlas benchmark studies have revealed substantial discrepancies in mutation calls used at major centers. 26 Although DNA from patient PBMCs has been used in some studies as a control to filter out germline mutations detected in solid tumors, different criteria are used by different investigators to define germline or somatic mutations. 25, 27 For example, a variant with a 10% allele frequency in both normal and tumor samples is classified with high confidence as a germline variant. 27 In our previous study, we also used an allele frequency of 10% as a cutoff to compare mutations detected in primary tumors and PDXs. However, because only a small fraction of total cfDNA may be derived from tumor cells, most tumor-specific mutations had allele frequencies < 10% in cfDNA. Therefore, we used an allele frequency of 1% as a cutoff to compare mutation calls among the samples. The reduction of cutoff values leads to a challenge in distinguishing between positive and false-positive calls because many possibly false-positive or noise calls were detected in all samples with similarly low allele frequencies. None of these background mutations had allele enrichment in primary tumor and PDX samples, so it is unlikely that these mutation calls were derived from the contamination of positive mutations in cfDNA because the 2 samples were present in the same compartment (blood). However, because most of these background mutations were repeatedly detected in different types of samples from the same patients as well as PBMC samples from different patients, it is likely that the mutations were derived from repetitive or homologues sequences present in the human genome.
Accumulating studies have demonstrated that the mutational analysis of cfDNA can be used to detect mutations in solid tumors and to monitor treatment responses and disease progression in cancer patients. [1] [2] [3] 28, 29 Our results support these previous reports in terms of the detection of tumor-specific mutations in cfDNA. Nevertheless, our results reveal that in the absence of primary tumor tissues or mutational data from primary tumors, it is necessary to increase the specificity of mutation callings in cfDNA by a parallel analysis of patients' PBMCs and by the filtering of mutation callings detected in possible homologous sequences.
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